Search Within

Naiyer A Rizvi

Formats
  1. Meeting Abstract (108)
  2. Journal Article (57)
  3. Research Letter (1)
Groups
  1. Department of Medicine (112)
  2. Solid Tumor Oncology Division (112)
  3. Thoracic Oncology (97)
  4. GSK Faculty (34)
  5. Department of Pathology and Laboratory Medicine (32)
  6. Radiology, Department of (30)

More Groups

People
  1. Mark Kris (71)
  2. Christopher Azzoli (37)
  3. Vincent Miller (37)
  4. Gregory Riely (30)
  5. Lee Krug (29)
  6. Matthew Hellmann (22)

More People

Years
  1. 2019 (1)
  2. 2018 (3)
  3. 2017 (6)
  4. 2016 (7)
  5. 2015 (18)
  6. 2014 (37)

More Years

Publications
  1. Journal of Clinical Oncology (65)
  2. Journal of Thoracic Oncology (28)
  3. Clinical Cancer Research (9)
  4. Annals of Oncology (8)
  5. International Journal of Radiation Oncology, Biology, Physics (8)
  6. Cancer Chemotherapy and Pharmacology (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (65)
  2. Elsevier Inc. (40)
  3. American Association for Cancer Research (13)
  4. Wiley Blackwell (10)
  5. Oxford University Press (8)
  6. Springer (8)

More Publishers

Results (166)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tumor mutational load predicts survival after immunotherapy across multiple cancer types
    Research Letter

    Samstein, R. M.; Lee, C. H.; Shoushtari, A. N.; Hellmann, M. D.; Shen, R.; Janjigian, Y. Y.; Barron, D. A.; Zehir, A.; Jordan, E. J.; Omuro, A.; more...
    Nature Genetics (2019)

    Fulltext@MSK | Save
  • Treatment outcomes of cutaneous adverse events to immune checkpoint inhibitors
    Meeting Abstract

    Wu, J.; Freites-Martinez, A.; Hellmann, M. D.; Rosenberg, J. E.; Motzer, R. J.; Chapman, P. B.; Rizvi, N. A.; Geskin, L. J.; Reed, V. A.; Dusza, S. W.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Prospective validation of prognostic scores to improve patient selection for immuno-oncology trials
    Meeting Abstract

    Massard, C.; Segal, N. H.; Cho, D. C.; Papadimitrakopoulou, V. A.; Rizvi, N. A.; Cho, B. C.; Yu, L.; Yang, H.; Hsieh, H. J.; Zhang, J.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Nivolumab plus erlotinib in patients with EGFR-mutant advanced NSCLC
    Journal Article

    Gettinger, S.; Hellmann, M. D.; Chow, L. Q. M.; Borghaei, H.; Antonia, S.; Brahmer, J. R.; Goldman, J. W.; Gerber, D. E.; Juergens, R. A.; Shepherd, F. A.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients
    Meeting Abstract

    Sanborn, R. E.; Pishvaian, M. J.; Kluger, H. M.; Callahan, M. K.; Weise, A. M.; Lutzky, J.; Yellin, M. J.; Rawls, T.; Vitale, L.; Halim, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Association of liver metastases (LM) with survival in NSCLC patients treated with durvalumab (D) in two independent clinical trials
    Meeting Abstract

    Paz-Ares, L. G.; Shen, K.; Higgs, B. W.; Morehouse, C.; Rizvi, N. A.; Segal, N. H.; Jin, X.; Zheng, Y.; Narwal, R.; Gupta, A. K.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • First-line nivolumab monotherapy and nivolumab plus ipilimumab in patients with advanced NSCLC: Long-term outcomes from CheckMate 012
    Meeting Abstract

    Gettinger, S.; Rizvi, N.; Chow, L.; Borghaei, H.; Brahmer, J.; Shepherd, F.; Ready, N.; Gerber, D.; Antonia, S.; Goldman, J. W.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057)
    Journal Article

    Horn, L.; Spigel, D. R.; Vokes, E. E.; Holgado, E.; Ready, N.; Steins, M.; Poddubskaya, E.; Borghaei, H.; Felip, E.; Paz-Ares, L.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)
    Journal Article

    Peters, S.; Gettinger, S.; Johnson, M. L.; Jänne, P. A.; Garassino, M. C.; Christoph, D.; Toh, C. K.; Rizvi, N. A.; Chaft, J. E.; Costa, E. C.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): Results of an open-label, phase 1, multicohort study
    Journal Article

    Hellmann, M. D.; Rizvi, N. A.; Goldman, J. W.; Gettinger, S. N.; Borghaei, H.; Brahmer, J. R.; Ready, N. E.; Gerber, D. E.; Chow, L. Q.; Juergens, R. A.; more...
    Lancet Oncology (2017)

    Fulltext@MSK | Save